In the gene panel test in the present case, besides ERBB2 E401G, short variants of TP53, EZH2, BAP1 and FH, and homozygous deletions of CDKN2A and FANCC were co-existent (Fig. 1c), all of which are pathogenic variants and potential cancer driver genes. This evidence concerns the gene TP53 and cancer.